Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK
- Associated Disease
- lung acinar adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1121
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/5
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Acinar Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Erlotinib
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 23181703
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erlotinib | Resitance or Non-Reponse | true |